RPG Life Sciences (RPGLIFE) Q1 25/26 earnings summary

Executive summary

• Q1 FY26 revenue from operations was ₹165.4 crore, a 2.1% decrease year-over-year, with EBITDA at ₹40.7 crore and PAT at ₹26.3 crore, both showing slight declines in margin compared to Q1 FY25.

• Unaudited financial results for the quarter ended June 30, 2025, were approved by the Board and reviewed by auditors, with no material misstatements identified.

• Domestic Formulations contributed 69% of sales, International Formulations 19%, and APIs 12%, with domestic and international segments showing growth but API impacted by a fire incident.

• Business transformation focuses on building mega brands, expanding global presence, and sustainable operations, supported by significant capex and digital initiatives.

Financial highlights

• Revenue from operations for the quarter was ₹16,892 lakhs, up from ₹14,309 lakhs in the previous quarter and ₹16,542 lakhs year-over-year.

• EBITDA margin for Q1 FY26 was 24.1%, down from 25.1% in Q1 FY25; PAT margin was 15.6%, slightly up from 16.2% last year.

• Domestic Formulations sales grew 9.5% year-over-year, International Formulations declined 2.7%, and API sales dropped 22.4% due to operational disruption.

• Net profit for the quarter was ₹2,629 lakhs, compared to ₹11,735 lakhs in the previous quarter (which included exceptional gains) and ₹2,676 lakhs year-over-year.

• Company remains debt-free, with robust cash flows and no debt-funded capex.

Outlook and guidance

• Strategic focus on portfolio development, mega-brand building, API business growth, digital transformation, and M&A.

• Ongoing capex and plant modernization to support expansion in regulated and emerging markets.

• The company continues to operate normally post-fire incident, with unaffected manufacturing blocks and ongoing insurance claim processes.